Celastrol delays hepatic steatosis and carcinogenesis in a rapid AKT/c-Met-transfected hepatocellular carcinoma modelviasuppressing fatty acid synthase expression and AKT/ERK phosphorylation

Abstract

Although the suppressing effects of celastrol on hepatocellular carcinoma (HCC) have been demonstrated, evidence for the targeting of fatty acid synthetase (FASN) in the development of HCC by celastrol is still rare.In this study, the effect of celastrol on a rapid HCC model featuring co-activation of AKT/c-Met oncogenes in mice was studied. The effect of celastrol on the alpha-fetoprotein level in the liver and serum was also

Celastrol-Loaded Galactosylated Liposomes Effectively Inhibit AKT/c-Met-Triggered Rapid Hepatocarcinogenesis in Mice

“…Celastrol, a proteasome inhibitor extracted from Tripterygium wilfordii Hook F, has been proven to inhibit malignant cell proliferation and promote apoptosis in various manners. , In our previous study, we have confirmed that hepatic steatosis and carcinogenesis induced by co-overexpression of AKT/c-Met in mice are relieved by intraperitoneal injection of free celastrol for 21 days; thus, celastrol may become a potential candidate for HCC therapy. However, poor water solubility and potential toxic side effects derived from celastrol itself and the solubilizer Cremophor EL, , such as severe weight loss found in our previous experiment, drove us to develop a safer and more effective treatment method.…”

Celecoxib attenuates hepatocellular proliferative capacity during hepatocarcinogenesis by modulating a PTEN/NF-κB/PRL-3 pathway

“…The protein preparation and immunoblotting procedures for hepatic tissues and cultured cells were performed as previously described. 19 The specic primary antibodies used in the immunoblotting assay are listed in ESI Table 2. †…”